TCM
IOVA icon

Towercrest Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Towercrest Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-25,000
Closed -$748K – 82
2020
Q1 		$748K Buy
+25,000
New +$663K 0.22% 48
2019
Q3 		– Sell
-9,000
Closed -$220K – 72
2019
Q2 		$220K Buy
+9,000
New +$136K 0.06% 67

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Towercrest Capital Management's IOVA Position: Q2 2020 in Review

Towercrest Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2020, closing a stake of 25,000 shares — an estimated $748K sold.

Towercrest Capital Management first reported a position in IOVA in Q2 2019 and held it in 2 quarters. The position peaked at $748K in Q1 2020. 257 funds tracked by Wall St. Rank hold IOVA as of Q2 2020.

  • Towercrest Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2020 after selling out during the quarter.
  • Towercrest Capital Management sold 25,000 Iovance Biotherapeutics shares in Q2 2020, an estimated $748K.
  • Towercrest Capital Management first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 2 quarters.
  • Towercrest Capital Management's Iovance Biotherapeutics position peaked at $748K in Q1 2020.
  • 257 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2020.

Based on Towercrest Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.